Document:

Exhibit 10.2

                                                SUMMARY
                                                REPORT
                                                BEE URANIUM PROPERTY

                                                Harrison Hot Spring, BC

                                                November 2011

<PAGE>
                                TABLE OF CONTENTS

                                                                            PAGE
                                                                            ----

EXECUTIVE SUMMARY                                                              3

1.0      INTRODUCTION                                                          4

          1.1     TERMS OF REFERENCE                                           4

          1.2     LOCATION AND ACCESS                                          5

          1.3     TOPOGRAPHY, CLIMATE, VEGETATION                              6

          1.4     PROPERTY STATUS                                              7

          1.5     PREVIOUS WORK                                                7

 2.0      GEOLOGY                                                              7

          2.1     REGIONAL GEOLOGY                                             7

          2.2     PROPERTY GEOLOGY                                             7

 3.0      CONCLUSIONS AND RECOMMENDATIONS                                     10

 4.0      REFERENCES                                                          11

FIGURES

1. BEE URANIUM PROPERTY BC LOCATION MAP                                        4

2. BEE URANIUM PROPERTY REGIONAL LOCATION MAP                                  5

3. BEE URANIUM PROPERTY MAP                                                    6

4. BEE URANIUM GEOLOGY MAP                                                     8

                                       2
<PAGE>
EXECUTIVE SUMMARY

1.   The Bee  Uranium  Property  (Minfile  092HSW110)  is  mainly  underlain  by
     intrusive rocks of the Oligocene (Tertiary) age Chilliwack  Batholith.  The
     property covers the contact between Upper Jurassic Kent Formation sediments
     and hornblende granodiorite of the Chilliwack Batholith.

2.   Radioactive  pegmatite  occurs  in  silicified   hornblende   granodiorite,
     containing a uranium mineral,  likely  uraninite or uraniferous  magnetite.
     Chalcopyrite and malachite are also found in the mineralized  zone.  Cobalt
     occurs as coatings  of  erythrite  (cobalt  bloom),  the  primary  mineral,
     possibly cobaltite, is unknown.

3.   A  geochemical  soil  anomaly in the  vicinity  of the main  showing can be
     followed for 50 to 150 metres in an east-west direction, indicating further
     extensions to the known mineralization.

4.   A proposed work program includes construction of a control grid, geological
     mapping and rock sampling, a soil and silt geochemical sampling program, IP
     and radiometric geophysical surveys, and trenching.  Based on a compilation
     of these  results,  a diamond drill program will be designed to explore and
     define the potential resources.

                                       3
<PAGE>
1.0 INTRODUCTION

1.1 TERMS OF REFERENCE

This summary  report is a compilation  of geological  data  currently  available
regarding the Bee Uranium Property, located approximately 3 kilometres southwest
of the resort town of Harrison  Lake,  B.C.  Historical  information  from Laird
Exploration  Ltd. files,  the BC Department of Mines,  the Geological  Survey of
Canada and other sources has been reviewed and used where pertinent.

                     [MAP SHOWING PROPERTY BC LOCATION]

                   FIG. 1 BEE URANIUM PROPERTY BC LOCATION MAP

                                       4
<PAGE>
1.2 LOCATION AND ACCESS

The property is located on the lower,  east slope of Mount Agassiz,  to the west
of Miami Creek.  Easy access to the property is provided from the nearby town of
Harrison Hot Springs.

Access is gained by traveling approximately 3 kilometres south from Harrison Hot
Springs  along  Highway No. 9. At this point,  a powerline  road is traveled for
approximately  800 metres west from  Highway 9 to Miami  Creek.  The Bee showing
area is easily  accessed  from this point,  lying at an elevation of 150 metres,
immediately west of Miami Creek.

The Bee mineral claim lies within the New  Westminster  Mining Division at 49(0)
16.5' north latitude and 121(0) 48' west longitude.

                    [MAP SHOWING PROPERTY REGIONAL LOCATION]

                FIG. 2 BEE URANIUM PROPERTY REGIONAL LOCATION MAP

                                       5
<PAGE>
1.3 TOPOGRAPHY, CLIMATE, VEGETATION

The property is found near the southern  tip of the Pacific  Ranges,  which is a
physiographic  subdivision of the Coast  Mountains.  The slopes of Mount Agassiz
are steep and rugged, with numerous rock bluffs.

The current mineral property  occupies the steep easterly slopes of Mt. Agassiz,
ranging from about 600 metres  elevation on Mt. Agassiz to about 50 metres along
Miami Creek. The Bee mineral showing is at 150 metres  elevation,  near the base
of Mt. Agassiz.

The mineral  property is covered by coniferous  forest  consisting of fir, cedar
and hemlock.  Swampy brush is found along the sides of Miami Creek.  The climate
is moderate with warm summers and cool rainy winters.

                       [MAP SHOWING BEE URANIUM PROPERTY]

                         FIG. 3 BEE URANIUM PROPERTY MAP

                                       6
<PAGE>
1.4 PROPERTY STATUS

The Bee  Property  comprises  one mineral  claim  containing  6 cell claim units
totaling 126.45 hectares:

     BC Tenure #        Work Due Date        Cells      Total Area (Hectares)
     -----------        -------------        -----      ---------------------
       928770            Nov. 9, 2012          6               126.45

1.5 PREVIOUS WORK

Other than  radiometric,  mapping and  geochemical  surveys carried out in 1978,
there  is very  little  documented  information  pertaining  to the Bee  mineral
showing.  Some hand  trenching and blasting had been carried out at some time in
the past, but there are no references to this work.

In 1978, an  exploration  program  consisting of geologic  mapping,  radiometric
surveys and soil sampling was carried out to locate  potential  areas of uranium
mineralization,  in proximity to the Bee mineral showing area. This  exploration
work was carried out on behalf of Jet-Star Resources Ltd. of Vancouver,  British
Columbia.

2.0 GEOLOGY

2.1 REGIONAL GEOLOGY

The Bee  occurrence  area is underlain by  Lower-Middle  Jurassic  Harrison Lake
Formation rocks comprised of intermediate to acidic flows and pyroclastics,  and
the Upper Jurassic Kent Formation conglomerate, chert and tuffs. These rocks are
intruded by the Oligocene Chilliwack Batholith.  The property covers the contact
between  Kent  Formation   conglomerate  and  hornblende   granodiorite  of  the
Chilliwack Batholith.

2.2 PROPERTY GEOLOGY

The main  area of  interest  on the  property  is an  outcropping  of  siliceous
pegmatitic  rock composed mainly of white to clear quartz  enveloping  subhedral
crystals of potash  feldspar (up to 8 cms long) and  fragments  of  granodiorite
host rock.  The  outcrop is  approximately  6 metres in  diameter  with  lightly
altered  hornblende-biotite  host rock to the west and north. A light dusting of
sericite  is  evident  in  the  granodiorite  and  to a  greater  degree  in the
pegmatite.

                                       7
<PAGE>
                [MAP SHOWING GEOLOGY OF THE BEE URANIUM PROPERTY]

                 FIG. 4 GEOLOGY MAP OF THE BEE URANIUM PROPERTY

                                       8
<PAGE>
Significant  northwest  trending  fault zones are evident as fault scarps in the
immediate area.  Faulting and to a lesser degree fracturing at 005(0) and 340(0)
is indicated adjacent to the mineral zone.

Mineralization is predominantly within the pegmatite or coarse-grained  granitic
extrusion.  An unidentified  uranium mineral,  possibly uraninite or uraniferous
magnetite  occurs as sporadic fine  disseminated  black  crystals in association
with clusters of  fine-grained  pyrite.  A greenish  yellow  secondary  mineral,
possibly phosphuranylite is also evident through the rock matrix.

Occasional  patches of  chalcopyrite  with  splashes of malachite  and erythrite
(cobalt bloom) occur  sporadically  within the zone.  Pale purplish  fluorite is
present in association with the quartz.

A two-metre  chip sample  across a portion of the mineral zone  assayed  0.020 %
uranium oxide or 0.18 Kg per tonne.

The results of the radiometric and soil sampling surveys were inconclusive.  The
radiometric survey indicated that the Bee showing is quite localized,  however a
145-sample  geochemical  soil survey  showed an anomaly of higher  than  average
uranium  values  extending  along an east-west  trend for a minimum length of 50
metres to a maximum of 150 metres.

There is potential in this  geological  environment to form a sandstone-  hosted
uranium deposit in sediments of the Kent Formation similar to the large deposits
in the Athabaska Basin, Saskatchewan.  The mineral associations are also similar
to Olympic-Dam style mineralization. Neither model type has been explored for in
this area, an exploration  program should test the potential of these geological
models.

                                       9
<PAGE>
3.0 CONCLUSIONS AND RECOMMENDATIONS

The Bee Uranium Property  contains  mineralization  that is classified as a Rare
Element Pegmatite.  Economic deposits of this type are not recognized in British
Columbia;  however they can be considered important sources of the rare elements
niobium and yttrium.  It is yet  uncertain  what  potential  exists for locating
economic levels of uranium on the Bee property.

A proposed work program  includes  construction  of a control  grid,  geological
mapping  and rock  sampling  of surface  showings,  a soil and silt  geochemical
sampling program,  IP and radiometric  geophysical  survey,  and rock trenching.
Based on a  compilation  of these  results,  a  diamond  drill  program  will be
designed to explore and define the potential resources.

The  anticipated  costs of this  development  are  presented  in three  results-
contingent stages.

PHASE 1

Reconnaissance geological mapping, prospecting and rock sampling.    $ 25,000.00

PHASE 2

Detailed geological mapping and rock sampling, grid construction,
soil and silt geochemical survey, IP survey, establish drill and
trenching targets.
                                                                     $100,000.00
PHASE 3

1000 meters of diamond drilling including geological
supervision, assays, report and other ancillary costs.               $175,000.00
                                                                     -----------
TOTAL                                                                $300,000.00
                                                                     ===========

                                       10
<PAGE>
4.0 REFERENCES

Laird,   James,  Laird  Explorations  Ltd.  Prospector  and  Mining  Exploration
Contractor for more than 25 years, provided prospecting notes on the geology and
exploration.

Mark, David G. (1978)
Geophysical Report on a Radiometric Survey, Bee Claim Group, Harrison Lake Area,
Geotronics Surveys Ltd.

Mark, David G, (1978)
Geochemical  Report on a Soil Sampling  Survey,  Bee Claim Group,  Harrison Lake
Area, Geotronics Surveys Ltd. for Jet-Star Resources Ltd. Assessment Report 6790

Monger, J.W.H. (1970)
Hope Map-Area, West Half, British Columbia
Geological Survey of Canada, Paper 69-47

Monger, J.W.H. (1989)
Geology, Hope, British Columbia
Geological survey of Canada, Map 41-1989

Sookochoff, L. (1977)
Geological Report on the Bee Property for Jet-Star Resources Ltd.

Sookochoff, L. (1978)
Geological Report on the Bee Property for Jet-Star Resources Ltd.

Thomson,  Gregory R.,  Geoscientist & Consulting  Geologist of 25 years Provided
notes and personal  experience of mineral  exploration  and local geology gained
while working in the Province of British Columbia

                                       11License Agreement

 Exhibit 10.17 
 LICENSE AGREEMENT 
 This License Agreement (“Agreement”)
is entered into by and between KaloBios Pharmaceuticals, Inc. (“KaloBios”), with offices at 3427 Hillview Ave, Suite 200, Palo Alto, CA, and Novartis International Pharmaceutical Ltd. (“NIP”), having its principal place of
business at Hamilton, Bermuda, on March 16, 2007 (“Effective Date”). NIP and its Affiliates shall be collectively referred to as “Novartis”. Accordingly, the Parties agree as follows: 

1. Definitions. 
 1.1 An
“Affiliate” means any Person who directly or indirectly controls or is controlled by or is under common control with a Party. For purposes of this definition, “control” or “controlled” means ownership directly or
through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any
other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity, or the
ability to cause the direction of the management or policies of a corporation or other entity. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum
percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence; provided that such foreign investor has the power to
direct the management and policies of such entity. For purposes of this Agreement, NIP and the Novartis Institute for Functional Genomics, Inc., dba the Genomics Institute of the Novartis Research Foundation (“GNF”) are each considered
Affiliates of the other. NIP shall be liable to KaloBios for all acts and omissions of its Affiliates as if performed by NIP under this Agreement. 
 1.2 “Collaboration Agreement” shall mean the Collaboration Agreement entered into by and among KaloBios, Novartis Pharma AG, and GNF on May 19, 2006 (as amended). 

1.3 “Completion Standard” shall mean the set of quantitative criteria, agreed upon by scientists from NIP or its
designated Affiliate and KaloBios in good faith, which represent reasonable metrics by which to evaluate NIP’s capability to successfully develop a Humaneered Antibody independent of KaloBios and to define the achievement of the Full Technology
Transfer (as defined in Section 3.3). The Completion Standard shall be deemed satisfied when NIP or its designated Affiliate has developed a Humaneered Antibody that has a binding affinity of at least 50% of that of the parent murine antibody
from which the Humaneered Antibody was developed. 
 1.4 “Control” shall mean the legal authority or right of a
Party to grant a license or sublicense of intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or
misappropriating the proprietary or trade secret information of a Third Party. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

 1.5 “Humaneering Technology” shall mean inventions (whether or not
patentable), processes, formulas, technology, reagents, protocols and know-how as set out in Exhibit A (as well as other such items that are not listed in Exhibit A but are used by KaloBios as of the Effective Date and are necessary to create such
engineered antibodies), Controlled or used by KaloBios as of the Effective Date comprising the method for creating engineered antibodies from Starting Antibodies. However, “Humaneering Technology” shall not include any commercially
available equipment, reagents or other materials. 
 1.6 “Humaneered Antibody” shall mean
(i) an engineered immunoglobulin protein or (ii) a fragment thereof less than the full-length antibody form (including, without limitation, Fv, Fab, and F(ab’)2, single-chain antibody, or other moiety which, in each case, includes at least one CDR (or fragment thereof) and is
capable of immunospecific binding); the development and manufacture of which incorporated Humaneering Technology. 
 1.7
“Novartis” shall mean NIP and its Affiliates, collectively (except as otherwise set forth in this Agreement). 

1.8 “Parties” shall mean KaloBios and NIP, and each individually shall be a “Party.” 

1.9 “Patents” shall mean any issued patent(s) and pending patent applications in any country, including, but not limited
to, all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions and supplementary patent certificates thereof.

 1.10 “Person” shall mean any individual, corporation, partnership, association, joint-stock company, trust,
unincorporated organization or government or political subdivision thereof. 
 1.11 “Proprietary Information”
shall mean information relating to the disclosing Party’s business, including, without limitation, technical drawings, know-how, formulas, chemical and biological compositions, processes, ideas, and other technical, business, financial,
customer and product development plans, forecasts, strategies and information. Notwithstanding the foregoing, nothing will be considered “Proprietary Information” unless either (a) it is or was disclosed in tangible form and is
conspicuously marked “Confidential”, “Proprietary” or the like or (b) it is or was disclosed in non-tangible form and identified as confidential at the time of disclosure, except that the Humaneering Technology shall be
considered KaloBios’ Proprietary Information whether or not marked or identified as such. 
 1.12 “Proprietary
Rights” shall mean patent rights, copyrights, trade secret rights and all other intellectual property rights. Proprietary Rights shall include rights in KaloBios’ proprietary human antibody libraries, targets and technology, as
described in Exhibit A, including without limitation information, know-how, methods and processes relevant thereto, and all intellectual property rights related to any of the foregoing, as of the Effective Date or during the Term of this Agreement,
including without limitation any Patents controlled by KaloBios which are necessary and would be otherwise infringed to make, have made, use, sell, export and import a Humaneered Antibody. Such Patents include, for example, those patents and patent
applications listed on Exhibit B. 
  
 [***] CONFIDENTIAL PORTIONS OF
THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 2 

 1.13 “Starting Antibody” shall mean (i) an
immunoglobulin protein or (ii) a fragment thereof less than the full-length antibody form (including, without limitation, Fv, Fab, and F(ab’)2, single-chain antibody, or other moiety which, in each case, includes at least one CDR (or fragment thereof) and is
capable of immunospecific binding). 
 1.14 “Third Party” shall mean any Person other than a Party and its
Affiliates. 
 1.15 “Transfer Plan” shall mean a plan to achieve the Completion Standard. 

2. License; Restrictions. 

2.1 Subject to all the terms and limitations of this Agreement (including, without limitation, the Target Exclusion defined below),
KaloBios hereby grants Novartis a perpetual, worldwide, non-exclusive, non-sublicensable, non-transferable, royalty-free license under its Proprietary Rights in Humaneering Technology, solely to: (i) use Humaneering Technology for
Novartis’ internal research and development purposes; provided, however, that no V-segment libraries, Vheavy expression vectors, Vkappa expression vectors, or Vlambda expression vectors provided to Novartis by KaloBios may be possessed by or
reside at, nor may any other Humaneering Technology be practiced by, any Person that is not an Affiliate of NIP as of the Effective Date (and the foregoing shall not be licensed activity under this Section 2.1); and (ii) make, have made,
use, sell, offer to sell and import Humaneered Antibodies developed by Novartis. 
 2.2 KaloBios grants no license, by
implication or otherwise, except for the license expressly set forth in Section 2.1. Neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) directly or indirectly use or otherwise exploit any
Humaneering Technology under a “fee-for-service” type of arrangement (as that term is understood in the industry) for the benefit of any Third Party (excluding commercial, collaborative or other similar arrangements with a Third Party).

 2.3 As a material inducement for KaloBios to enter into this Agreement: 

(a) For the period beginning on the Effective Date and ending on the date five years from KaloBios’ receipt of all amounts due under
Section 6 below, neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) use Humaneering Technology or KaloBios Proprietary Information to directly or indirectly research, develop or manufacture (or
prepare to do so) any Humaneered Antibody against any of the targets set forth in Exhibit C, which are presently in KaloBios’ product pipeline (the “Target Exclusion”); and 

(b) For the period beginning on the Effective Date and ending on the date two years from KaloBios’ receipt of all amounts due under
Section 6 below, neither NIP nor its Affiliates shall (nor shall any of them enable or permit any Third Party to) develop or commercialize a Humaneered Antibody against a target of a Pre-Existing Project or a Committed Project (as those terms
are defined in the Collaboration Agreement) unless the milestone payments and royalties for that Target are paid as set forth in Sections 6.4 and 6.5 of the Collaboration Agreement or Novartis has exercised the Buy-Out Option set forth in
Section 6.7 of the Collaboration Agreement. 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 3 

 For the avoidance of doubt, the foregoing restrictions apply to all research and development activities that
use Humaneering Technology or KaloBios Proprietary Information. 
 3. Technology Transfer to NIP, or its Designated Affiliate.

 3.1 To enable Novartis to exercise the foregoing license, KaloBios will: (i) disclose and provide to NIP, or its
designated Affiliate, as soon as reasonably practicable following the Effective Date, the reagents and protocols as described in Exhibit A (the “Initial Technology Transfer”); and (ii) transfer the remainder of the tangible
embodiments of Humaneering Technology as described in Exhibit A and provide NIP, or its designated Affiliate, reasonable access to KaloBios scientists at a Novartis facility designated by NIP until NIP or its designated Affiliate has, at the
Novartis facility, developed one Humaneered Antibody that satisfies the Completion Standard (the “Full Technology Transfer”). NIP shall identify the target against which it plans to develop the Humaneered Antibody for purposes of
completing the Full Technology Transfer within two weeks of the Effective Date. 
 3.2 When KaloBios believes the Initial
Technology Transfer has been completed, KaloBios will notify NIP (or its designated Affiliate). NIP (or its designated Affiliate) will accept or reject completion of the Initial Technology Transfer in writing within thirty (30) calendar days
from receipt of such notice. NIP (or its designated Affiliate) may reject the Initial Technology Transfer only if the transfer failed in some material respect to meet the requirements therefor stated in Exhibit A and NIP’s (or its designated
Affiliate’s) notice to that effect includes a reasonably detailed description of such failure. Failure to give proper written notice of acceptance or rejection within the acceptance period will constitute acceptance. If the Initial Technology
Transfer is accepted, KaloBios will be conclusively presumed to have met its obligations with respect thereto and NIP shall pay KaloBios the fees as set forth in Section 6 below. 

3.3 NIP will notify KaloBios of the completion of the Full Technology Transfer. However, KaloBios will be conclusively presumed to have
met its obligations with respect thereto (it will be deemed accepted) on the earlier of the date: (i) when the TCC (described in Section 4 below) determines that the first Humaneered Antibody developed by NIP (or any Affiliate) in
conjunction with KaloBios’ services under this Section 3 materially conforms to the requirement set forth in the Completion Standard; or (ii) six (6) months following acceptance of the Initial Technology Transfer (subject to
Section 3.4 below). 
 3.4 KaloBios will extend the six (6) month time period in Section 3.3(ii) by one
(1) month for each month that the TCC determines KaloBios has failed to meet its diligence obligations as described in Section 4.3(v), until the Completion Standard has been satisfied. 

3.5 Upon request by NIP, KaloBios agrees to provide reasonable consulting services to NIP, or its designated Affiliate at commercially
reasonable rates during the period beginning at the completion of the Full Technology Transfer. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 4 

 4. Governance. 
 4.1 The Parties will establish a Transfer Coordinating Committee (“TCC”), composed of two (2) representatives of KaloBios and two (2) representatives of NIP or its designated
Affiliate. 
 4.2 Within fifteen (15) days of the Effective Date, each Party will designate its initial members to serve on
the TCC. Each Party may replace its representatives on the TCC on written notice to the other Party. 
 4.3 The TCC shall have
the following responsibilities: (i) develop a mutually agreeable Transfer Plan within sixty (60) days of the Effective Date; (ii) monitor the schedules and progress of work pursuant to this Agreement; (iii) receive and submit
requests for information and/or assistance; (iv) generally oversee the day to day activities and relationship of the Parties pursuant to this Agreement; (v) documenting in outline format each month’s progress towards achievement of
the Completion Standard, where the TCC will specifically report in writing if KaloBios has failed to use commercially reasonable efforts to diligently transfer the Humaneering Technology as required herein; and (vi) report to NIP the
achievement of the Completion Standard. Notwithstanding anything to the contrary, the TCC is not authorized to amend, alter or extend this Agreement in any manner. 
 4.4 The TCC shall meet in person or by teleconference every four (4) weeks for the duration of the Initial and Full Technology Transfer (“Technology Transfer Period”) and quarterly
during the Disclosure Period. 
 4.5 In the event of a disagreement among the TCC members, the matter will be resolved in
accordance with Section 20; provided, however, that in the case of a disagreement with respect to Section 4.3(v), one of Novartis’ representatives (as designated by Novartis in advance as the chairperson of the TCC) shall be empowered
to cast two votes, as compared to one vote for each of the other three TCC members. 
 5. Intellectual Property. 

5.1 Ownership. As among the Parties, each Party and its respective Affiliates will be the sole owner of the intellectual property
rights in any invention of which only its employees and Third Party contractors are inventors, and each Party and its respective Affiliates will jointly own the intellectual property rights in all inventions of which its and another Party’s or
its respective Affiliates’ employees or contractors are joint inventors (“Joint IP”). Joint IP may be exploited and non-exclusively licensed to Third Parties by any Party without accounting to or further approval of the joint
owner(s). 
 5.2 Improvements. 
 (a) The license grant set forth in Section 2.1 shall include, at no additional charge to Novartis, any modification, extension, enhancement or improvement that is based on or derived from the
Humaneering Technology (“Improvements”), except Improvements created specifically in connection with a bona fide agreement with a Third Party, which KaloBios makes, conceives, or reduces to practice before the later of:
(i) thirty (30) months following completion of the Full Technology Transfer, or (ii) thirty-six (36) months following the Effective Date (the “Disclosure Period”). KaloBios shall provide reasonable consulting
services with respect to 
  
 [***] CONFIDENTIAL PORTIONS OF THIS
DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 5 

 
such Improvements as provided hereunder. Notwithstanding anything to the contrary, and for clarity, if KaloBios is acquired (whether in a merger, acquisition, change of control transaction, or
the like), no pre-existing intellectual property or technology of the acquiring Person shall be deemed an “Improvement.” For the avoidance of doubt, “Improvements” only include inventions, processes, formulas, technology,
reagents, protocols or know-how, and any corresponding intellectual property rights, relevant to developing Humaneered Antibodies from Starting Antibodies and do not include, for example, specific Humaneered Antibodies developed by Novartis under
its license. 
 (b) The Parties agree that nothing in this Agreement is intended to enable Novartis to prevent or restrict
KaloBios from practicing (at any time) its existing technology or any Improvements. Accordingly, Novartis hereby grants back to KaloBios a perpetual, worldwide, royalty-free, non-exclusive, non-sublicensable license, to make, have made, use, sell,
offer to sell and import Humaneered Antibodies using any and all Improvements made, conceived or reduced to practice during the Disclosure Period by Novartis, excluding (for clarity) specific Humaneered Antibodies developed by Novartis which are
potential therapeutic products of Novartis. For the avoidance of doubt, (i) the foregoing grant back shall be deemed to include, without limitation, any invention that (alone or together with others) tends to define, describe or surround any
part of the Humaneering Technology or any Proprietary Right licensed hereunder, and (ii) this Section 5.2(b) (unlike Section 5.2(c)) does not require Novartis to actually transfer technology or know-how to KaloBios. 

(c) The Parties agree to promptly disclose all Improvements to one another during the Disclosure Period. To assist in the transfer of
such Improvements, each Party will (I) be entitled to have a development engineer observe the operations of the others related to the Humaneering Technology for up to one (1) month per year during the Disclosure Period and (II) make its
personnel reasonably available during the Disclosure Period to provide the other Party with reasonable information and assistance concerning Improvements upon request. 
 6. Fees and Payment Terms. 
 6.1 NIP will pay KaloBios a non-refundable fee
of [***]. The payment will be made as follows: (i) [***] (ii) [***] (iii) [***]. 
 6.2 All invoices shall
conform to the extent reasonably practicable to the form of invoice contained in Exhibit D. All payments due shall be paid in U.S. Dollars. All taxes related to any payments hereunder (except U.S. taxes on KaloBios’ net income) shall be
paid by Novartis and are not deductible from the payments due KaloBios. If Novartis is required by law to deduct or withhold any taxes from any amount payable to KaloBios hereunder, then the amount payable hereunder shall be increased so that after
making all required deductions and/or withholdings (including deductions and withholdings applicable to any additional amounts payable under this Section), KaloBios receives an amount equal to the amount it would have received had no such deductions
or withholdings been made, and Novartis shall, after making full payment of any such tax, provide KaloBios copies of tax receipts evidencing payment of such taxes. 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 6 

 7. Inspection While the license granted under Section 2.1 is in effect, KaloBios shall have the
right to appoint an internationally-recognized independent accounting firm reasonably acceptable to Novartis to inspect the relevant records and premises of Novartis to verify compliance with this Agreement. Before beginning its audit, the auditor
shall execute an undertaking acceptable to Novartis by which the auditor shall keep confidential all information reviewed during such audit. The auditor shall have the right to disclose to KaloBios its conclusions from the audit. Novartis shall make
its records and premises available for inspection by the auditor during regular business hours, upon receipt of reasonable advance notice from KaloBios, solely to verify Novartis’ compliance with this Agreement. Such inspection right shall not
be exercised more than once in any calendar year, unless the previous inspection revealed material non-compliance on the part of Novartis. KaloBios agrees to hold in strict confidence all information received and all information learned in the
course of any audit or inspection, except to the extent necessary for KaloBios to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order. KaloBios shall pay for
such inspections, as well as its own legal expenses associated with enforcing its rights with respect to any payments hereunder; except that in the event of Novartis’s noncompliance with any material term of this Agreement, Novartis shall pay
for such inspection. 
 8. Confidentiality. Except as allowed herein, each receiving Party will hold in confidence and not use or
disclose any Proprietary Information of the disclosing Party without the consent of the disclosing Party, and shall similarly bind its employees in writing. NIP may disclose KaloBios’ Proprietary Information to its Affiliates who have a need to
know such information for the purpose of exercising the rights and licenses granted hereunder. Each receiving Party shall not be obligated under this Section with respect to information such receiving Party can document (a) is or has become
readily publicly available without restriction through no fault of such receiving Party or its employees or agents, (b) is received without restriction from a Third Party lawfully in possession of such information and lawfully empowered to
disclose such information, (c) was rightfully in the possession of such receiving Party without restriction prior to its disclosure by the other Party, or (d) was independently developed by employees or consultants of such receiving Party
without access to such Proprietary Information. Each Party may disclose the other’s information that comprises Proprietary Information to the extent such disclosure is reasonably necessary in: (i) filing, prosecuting or defending
litigation; (ii) filing, prosecuting or defending patent rights that encompass the Humaneered Antibodies (but only to the extent that one Party gives its consent to another Party to make such disclosure, which consent shall not be unreasonably
withheld); or (iii) complying with applicable governmental regulations; provided, however, that if a Party is required to make any disclosure of the other Party’s secret or Proprietary Information, it will give reasonable advance notice to
the other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure confidential treatment of such Proprietary Information required to be disclosed. Upon any termination of this Agreement,
and upon request, each Party shall promptly return to the other all of the other Party’s Proprietary Information that is not the subject of an existing license granted hereunder. Each Party has the right to retain one copy of Proprietary
Information in their files for accounting and legal purposes. For eighteen (18) months from the Effective Date, neither GNF nor the Novartis Institutes for BioMedical Research (NIBR), an Affiliate of NIP, will, directly or indirectly, solicit
or induce any member of the KaloBios technical or scientific staff to leave the employ of KaloBios; the foregoing does not prohibit mass media 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 7 

 
“want ads” not specifically directed towards employees or consultants of a Party. Notwithstanding anything else, with respect to information disclosed by any Party outside of this
Agreement, this Agreement shall not expand, modify or otherwise supersede the terms and conditions of any non-disclosure or similar agreement entered into between KaloBios (on the one hand) and Novartis or any of their Affiliates (on the other
hand), which shall remain in full force and effect in accordance with its terms. 
 9. Patent Infringement and Enforcement Matters.

 9.1 Novartis shall mark, and shall ensure that its licensees and channel partners mark, products (or their containers or
labels) made, sold, or otherwise disposed of under this Agreement with the word “patent” or abbreviation “pat” and the applicable patent number(s), as KaloBios may notify Novartis from time to time if reasonably necessary to
protect KaloBios’ Proprietary Rights. 
 9.2 KaloBios may in its discretion take or not take whatever action it believes is
appropriate against any product or activity of any Third Party that may involve infringement or violation or an invalidity challenge of any Proprietary Right of KaloBios or Improvement to which KaloBios has a right to practice. 

9.3 Subject to Section 9.2, Novartis may in its discretion take or not take whatever action it believes is appropriate against any
product or activity of any Third Party that may involve infringement or violation or an invalidity challenge of any Proprietary Right relating to a Humaneered Antibody of Novartis. 

9.4 Notice. In the event that a Third Party at any time asserts a claim, or brings an action, suit or proceeding against a Party,
or any of its Affiliates or sublicensees, claiming infringement of such Third Party’s patent rights or unauthorized use or misappropriation of such Third Party’s know-how, based upon an assertion or claim arising out of any of the
activities taken in respect of Humaneering Technology or making, importing, use or sale of a Humaneered Antibody (such a claim, action, suit or proceeding, a “Third Party Infringement Claim”), such Party shall promptly notify the
other Party in writing of the claim or the commencement of such action, suit or proceeding, enclosing a copy of the claim and all papers served (to the extent not otherwise prohibited by law or contract). 

9.5 Defense of Third Party Infringement Claim. In the event of a Third Party Infringement Claim, and subject to the Indemnity
provisions set out in Section 12, the Party listed below shall assume control of the defense of such action, suit, proceeding or claim, and shall be entitled to settle any such claim against it in its sole discretion (but, for clarity, this
provision shall not give any Party the right to take any action or settle any claim on another Party’s behalf). 
 (a)
KaloBios, to the extent the Third Party Infringement Claim is directed against Humaneering Technology; and 
 (b) Novartis, to
the extent the Third Party Infringement Claim is directed against a Humaneered Antibody of Novartis. 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 8 

 The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. 

10. Term and Termination. 

10.1 Term. This Agreement will remain in effect until the expiration of the last to expire of KaloBios patent rights that claim
Humaneering Technology, unless earlier terminated pursuant to Section 10.2. 
 10.2 Termination. If any Party should
materially breach this Agreement, a non-breaching Party may terminate this Agreement upon 60 days notice (30 days in the case of nonpayment) unless the breach is cured within the notice period. If the allegedly breaching party disputes that it has
materially breached the agreement, the non-breaching Party may not terminate the Agreement until after the completion of the Dispute resolution procedures set forth in Article 20 (i.e. related to the escalation within each Party and the Mediation).

 10.3 Effect of Termination. In the event of any termination of this Agreement, each Party will return to the other all
Proprietary Information of such other Party (and all copies and extracts thereof). In the event of termination pursuant to Section 10.2 and subject only to the remainder of this Section 10.3 and to Section 10.4 below, all rights and
licenses granted under this Agreement shall immediately terminate. Notwithstanding any termination or expiration, all rights and obligations concerning accrued payments shall survive. The terms of Sections 1, 2.2, 2.3, 5.1, 5.2(b), 7-8, 9.1, 10.3,
10.4, 11-14 and 16-21 shall survive expiration or termination of this Agreement. Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain available. 

10.4 Optional Post-Termination Rights. 
 (a) In the event of termination by Novartis pursuant to Section 10.2, all rights and licenses granted to Novartis under this Agreement shall become irrevocable: (i) if Novartis notifies KaloBios
within thirty (30) days of such termination of its intent to exercise the rights under this Section 10.4(a); (ii) if Novartis promptly pays or has paid KaloBios in full any and all amounts that are contemplated to be paid to KaloBios
pursuant to Section 6 at the time of such termination; and (iii) subject to compliance with the surviving sections set forth in Section 10.3 above. 
 (b) In the event of any termination of this Agreement by KaloBios pursuant to Section 10.2, Novartis may continue to make, have made, use, sell, offer to sell and import Humaneered Antibodies
existing on the effective date of termination, subject to: (i) NIP notifying KaloBios within thirty (30) days of such termination of its intent to exercise the rights under this Section 10.4(b) (which notice shall include a reasonably
detailed description of all Humaneered Antibodies existing at that time, and the clinical or pre-clinical stage of development for each); (ii) Novartis’ compliance with all surviving provisions of this Agreement; and (iii) Novartis
paying KaloBios royalties and milestones on all such Humaneered Antibodies as if they were “Products” under the Collaboration Agreement (i.e. all amounts set forth in Sections 6.4 (Milestones) and 6.5 (Royalties) of the Collaboration
Agreement, reading 
  
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT
REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 9 

 
the term “Product” in such sections of the Collaboration Agreement as “Humaneered Antibody” for that purpose). Section 7 (Payments; Records) of the Collaboration
Agreement shall apply with respect to all amounts owed to KaloBios under this Section 10.4(b). If NIP or any of its Affiliates should materially breach this Agreement while this Section 10.4(b) is in effect, KaloBios may terminate all
rights granted under this Section upon 60 days notice (30 days in the case of nonpayment) unless the breach is cured within the notice period. 
 10.5 No Termination Payments. No Party shall incur any liability whatsoever for any damage, loss or expenses of any kind suffered or incurred by the other arising from or incident to any
termination of this Agreement (or any part thereof) by such Party which complies with the terms of the Agreement whether or not such Party is aware of any such damage, loss or expenses. 
 11. Limited Liability. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, EXCEPT FOR A PARTY’S BREACH OF CONFIDENTIALITY OR NIP’S OR ITS AFFILIATE’S BREACH OF SECTION 2.3,
NO PARTY SHALL BE LIABLE OR OBLIGATED WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT OR UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR: (I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES OR LOST PROFITS; OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES. MOREOVER, KALOBIOS SHALL NOT BE LIABLE UNDER ANY THEORY FOR ANY AMOUNTS IN EXCESS IN THE AGGREGATE OF THE FEES PAID TO IT HEREUNDER. 

12. Indemnity. 
 12.1
KaloBios will defend, indemnify and hold Novartis harmless against any claims, damages, settlements and expenses (including attorneys’ fees) in respect of injury (including death) to any persons or damage to any real or tangible property
arising out of (a) the negligence or willful misconduct of KaloBios in the performance of the services under Section 3 of this Agreement, and (b) a Third Party claim against Novartis resulting from a breach of the representations and
warranties set forth in Section 14.2; provided KaloBios shall not be liable for nor be required to indemnify Novartis in regard to any injury or damage caused by any negligence or willful misconduct on the part of Novartis’ development,
manufacture, use, sale, storage or handling of Humaneered Antibodies under this Agreement. This Section 12.1 states KaloBios’ entire obligation and Novartis’ sole remedy with respect to infringement of Third Party intellectual
property rights, and KaloBios’ liability under this Section shall be limited to a maximum of [***]. 
 12.2 Novartis will
defend, indemnify and hold KaloBios and its Affiliates harmless against any claims, damages, settlements and expenses (including attorneys’ fees) arising out of or relating to Novartis’s exercise of the rights granted under this Agreement
(including, without limitation, the manufacturing and clinical exploitation of Humaneering Technology or Humaneered Antibodies). 
 12.3 The indemnification obligations under this Section shall be conditioned upon the indemnified Party (a) promptly notifying the indemnifying Party of such claim; (b) turning over 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 10 

 
to the indemnifying Party sole control with respect to the defense and settlement of such claim; and (c) fully cooperating with the indemnifying Party in the defense and settlement thereof,
provided the indemnifying Party reimburses it for all out-of-pocket expenses incurred in providing such cooperation. An indemnified Party’s failure to promptly notify the indemnifying Party shall not relieve the indemnifying Party of its
obligations under this Section 12 except to the extent that the indemnifying Party can demonstrate damages attributable to such failure. 

13. Export Control. Each Party shall comply with all applicable export laws, restrictions, and regulations of any United States or foreign agency
or authority and will not export or re-export, or allow or authorize the export or re-export of, any Humaneered Antibody, technology or information it obtains or learns pursuant to this Agreement in violation of any such laws, restrictions or
regulations. 
 14. Warranty and Disclaimer. 
 14.1 Each Party represents and warrants to the other Party that: (i) it has full corporate power and authority to enter into and perform this Agreement, and (ii) neither its entering nor
performing this Agreement will violate any right of or breach any obligation to any Third Party under any agreement or arrangement between such Party and the Third Party. 
 14.2 KaloBios represents and warrants to Novartis that: (i) except with respect to the expression of immunoglobulins, the methods and libraries used in Humaneering Technology, if practiced in Europe
or North America, do not infringe any Third Party intellectual property right known to KaloBios as of the Effective Date; and (ii) KaloBios has not received written notice from any Third Party of infringement of a Third Party patent right by
the making, importing, use or sale of Humaneering Technology or a Humaneered Antibody. 
 14.3 OTHERWISE, NO PARTY MAKES ANY
WARRANTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF AND EACH PARTY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. KALOBIOS MAKES
NO WARRANTY REGARDING THE RESULTS OF USE OR SAFETY OR EFFICACY OF ANY ANTIBODY OR OTHER MATTER. 
 15. Publicity. The Parties will agree
upon the timing and content of any initial press release or other public communications relating to this Agreement and the transactions contemplated herein. 
 15.1 Except to the extent already disclosed in that initial press release or other public communication, no public announcement concerning the existence or the terms of this Agreement or concerning the
transactions described herein shall be made, either directly or indirectly, by any Party, except as may be legally required by applicable laws, regulations, or judicial order, without first obtaining the approval of the other Party and agreement
upon the nature, text, and timing of such announcement. 
 15.2 The Party desiring to make any such public announcement shall
provide the other Party with a written copy of the proposed announcement in sufficient time (no less than thirty (30) days) prior to public release to allow such other Party to comment upon such announcement prior to public release. 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 11 

 16. Relationship of the Parties. Notwithstanding any provision hereof, for all purposes of this
Agreement each Party shall be and act as an independent contractor and not as partner, joint venturer, or agent of the other and shall not bind nor attempt to bind the other to any contract. 
 17. Assignment. No Party shall have any right or ability to assign or transfer any obligations or benefits under this Agreement without the written consent of the other Party (and any unauthorized
purported assignment will be void), except that a Party may assign and transfer this Agreement and its rights and obligations hereunder to any Affiliate or to any Third Party who succeeds to all or substantially all its business or assets. This
Agreement will be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. 
 18. Notice. All
notices under this Agreement shall be in writing, and shall be deemed given when personally delivered or three days after being sent by prepaid certified or registered U.S. mail to the address of the Party to be noticed as set forth herein or such
other address as such Party last provided to the other by written notice. Any such notice or communication may also be delivered by hand or by facsimile to the appropriate addressee. Notices shall be sent: 

 

			
	If to KaloBios, to:	  	KaloBios Pharmaceuticals, Inc.
		  	Attn: Mark Alfenito
		  	3427 Hillview Ave, Suite 200
		  	Palo Alto, CA
		  	Fax: (650) 843-1896
		
	If to NIP, to:	  	Novartis International Pharmaceutical Ltd.
		  	Attn: President
		  	 P.O. Box HM 2899
 Hamilton
HM LX
 BERMUDA

		  	Fax: (441) 296-5083
		
	With a copy to:	  	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
		  	220 Massachusetts Avenue
		  	Cambridge, Massachusetts 02139
		  	Attention: Legal Dept.
		  	Fax: (617) 871-3354
		
		  	Genomics Institute of the Novartis Research Foundation
		  	Attn: General Counsel
		  	10675 John Jay Hopkins Drive
		  	San Diego, CA 92121
		  	Fax: (858) 812-1981

 19. Miscellaneous. The failure of any Party to enforce its rights under this Agreement at any time for any period
shall not be construed as a waiver of such rights. No changes or 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 12 

 
modifications or waivers are to be made to this Agreement unless evidenced in writing and signed by both Parties. In the event that any provision of this Agreement shall be determined to be
illegal or unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. In any action or proceeding to enforce rights under this
Agreement, the prevailing Party will be entitled to recover costs and attorneys fees. No liability or loss of rights hereunder shall result to any Party from delay or failure in performance (other than payment) caused by circumstances beyond the
reasonable control of the Party affected thereby. 
 20. Dispute Resolution. 

20.1 The Parties recognize that disputes as to certain matters relating to either Party’s rights and/or obligations hereunder may
arise from time to time. It is the objective of the Parties to establish procedures to facilitate, if at all possible, the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. Any dispute arising
between the Parties relating to, arising out of or in any way connected with the Agreement or any term or condition hereof, whether before or after termination of the Agreement, including but not limited to: (1) the performance by either Party
of its obligations hereunder; (2) the rights of either Party hereunder; and (3) any allegedly improper actions of either Party that may be deemed to be intentionally and/or negligently tortious conduct (a “Dispute”), will be
resolved as set forth in this Section 20. 
 20.2 Any Dispute shall first be brought to the attention of the Chief
Scientific Officers of the Parties (or their respective designees, who shall have sufficient authority to ensure acceptance and execution of any Dispute resolution that is reached). 

20.3 If the Chief Scientific Officers (or their designees) are unable to resolve such Dispute within forty-five (45) days of the
first presentation of such dispute to the Chief Scientific Officer, then such Dispute shall be referred to the Chief Executive Officers of each of the Parties (or their respective designees, who shall have sufficient authority to ensure acceptance
and execution of any Dispute resolution that is reached), who shall use their good faith efforts to mutually agree upon the proper resolution of the Dispute or an appropriate plan of action to resolve the Dispute. 

20.4 If any dispute is not resolved by the Chief Executive Officers of the Parties (or their designees) within thirty (30) business
days after such dispute is referred to them, or such longer period as the Chief Executive Officers (or their respective designees) may collectively agree, then any Party shall have the right to request non-binding mediation for such dispute
(“Mediation”). The Mediation shall be administered by the American Arbitration Association in accordance with its commercial mediation rules. Unless otherwise mutually agreed upon by the Parties, the Mediation proceedings shall be
conducted in San Diego. The Parties agree that they shall share equally the cost of the Mediation, including filing and hearing fees, and the cost of the mediator(s). Each Party shall have the right, at its own expense, to be represented by counsel
in such a proceeding. Each Party shall use commercially reasonable efforts to commence Mediation proceedings within thirty (30) days subsequent to the initial written request for such Mediation. If any unresolved matter is not resolved
following such Mediation, or in the event that such Mediation is not concluded: (i) within sixty (60) days subsequent to the first meeting of 
  

[***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 13 

 
the Parties in connection with such Mediation; or (ii) within ninety (90) days subsequent to the initial written request for such Mediation, then either Party shall have the right to
take such other action as is permitted under the relevant laws, taking into account the provisions of Section 21 (Governing Law and Venue). Notwithstanding the foregoing, nothing in this Section 20 shall limit a Party’s right to seek
injunctive or other equitable relief in court at any time. 
 21. Governing Law and Venue. This Agreement shall governed by the laws of
the state of California, without regard to conflicts of law principles. The Parties agree for all controversies under this Agreement, unless otherwise provided in Section 20, the State and Federal Courts of California shall have exclusive
jurisdiction. 
 [Signature page follows] 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION. 

  
 14 

 
			
	KALOBIOS PHARMACEUTICALS, INC
		
	By	 	 /s/ David W. Pritchard

	Name:	 	 David W. Pritchard

	Title	 	 Chief Executive Officer

		 	 KaloBios Pharmaceuticals, Inc.

	
	NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
		
	By	 	 /s/ Emil Brock

	Name:	 	 Emil Brock

	Title:	 	 Member of the Board

		
	By	 	 /s/ Robert L. Thompson

	Name:	 	 Robert L. Thompson

	Title:	 	 Member of the Board

  
 [***] CONFIDENTIAL PORTIONS OF THIS
DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 15 

 EXHIBIT A 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 EXHIBIT B 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 EXHIBIT C 
 [***] 
  
 [***]
CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  

 Exhibit D 
 Form of Invoice 
  

			
	Sender’s Logo	  	INVOICE
		
		  	INVOICE DATE:
	Street	  	[Month] [day] 200x
	Town, Country	  	
	Phone and Fax Nr.	  	INVOICE No.: XXX

  

			
	 Bill to: 
	  	For:
	 Novartis International Pharmaceutical Ltd.

“Hurst Holme”, 12 Trott Road

Att. Mr. Emil Bock/ Ms. Wendy Wiseman

P.O Box HM 2899
 Hamilton, HM LX
 Bermuda

and via fax, facsimile No. +1 441 296 5083
	  	

  

					
	 DESCRIPTION
	  	AMOUNT (USD)	 
	 	  	US$000’000	 
	 (milestone payment for event Y, according to paragraph XY of agreement ZZZ dated...)
	  			
		
	 Novartis Contract Code
	  			
		
	 Please specify the event for which the invoice is due
	  			
		
	 Please remit by wire transfer to:
	  			
		
	 Receiving Bank -
	  			
	 Swift Code -
	  			
	 ABA Number -
	  			
	 Credit Account -
	  			
	 Beneficiary -
	  			
		  	  
	  
	 
	 TOTAL
	  	 	000’000	  
		  	  
	  
	 

 If you have any questions concerning this invoice, contact ......... 

or e-mail to ......... 
 VAT - Reg. No.
Xxxxxxxxxx (if partner has one) 
 Best regards, 

 
 [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND SEPARATELY FILED
WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]